Newron Pharmaceuticals S.p.a.

Farmitalia Carlo Erba S.r.l.

Elena Barbanti

Patricia Salvati

Florian Thaler

Luca Benatti

Emanuela Izzo

Laura Faravelli

Carla Caccia

Ruggero Fariello

Renato Canevotti

Francesco Velardi

Francesco Ponzini

Tiziano Ruffilli

Luigi Bogogna

Claudia Besana

Roberto Pellicciari

Domenico Trizio

Orietta Veneroni

Fabrizio Marcucci

Marta Ghislieri

Fariello Ruggero

Claudia c/o Newron Pharmaceuticals SpA Besana

Florian c/o Newron Pharmaceuticals SpA Thaler

A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]propanamides, and their salts with pharmaceutically acceptable acids with high purity degree, in particular, with a content of dibenzyl derivatives impurities lower than 0.03%, preferably lower than 0.01% by weight. The process is carried out by submitting the Schiff bases intermediates 2-[4-(3- and 2-fluorobenzyloxy)benzylideneamino]propanamides to a reduction reaction with a reducing agent selected from sodium borohydride and potassium borohydride in an appropriate amount of an organic solvent selected from C-Clower alkanols, allowing the formation and presence during a substantial position of the reduction reaction course of a suspension of the Schiff base into the saturated solution of the Schiff base into the same organic solvent.

High purity 2-[4-(3- or 2-fluorobenzyloxy)benzylamino] propanamides and methods of use thereof

Methods of using certain &#x3b1;-aminoamide derivatives in the treatment of RLS and addictive disorders, The compounds of this invention are able to reduce or even stop the symptoms of RLS and addictive disorders substantially without side effects.

Alpha-aminoamide derivatives useful in the treatment of addictive disorders

A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]-propanamides and their salts with pharmaceutically acceptable acids with a high degree of purity, i.e. with a content of dibenzyl derivatives impurities lower than 0.03% by weight. The process is carried out by submitting a Schiff base intermediate to a reduction reaction with a reducing agent in an amount of organic solvent to allow the formation (and presence during a substantial portion of the reduction reaction) of a suspension of the Schiff base.

High purity 2-[4-(3- OR 2-fluorobenzyloxy)benzylamino]propanamides and methods of use thereof

The invention relates to the use of certain alpha-aminoamide derivatives in the treatment of RLS and addictive disorders. The compounds of this invention are able to reduce or even stop the symptoms of RLS and addictive disorders substantially without side effects.

&#x3b1;-Aminoamide derivatives useful in the treatment of restless legs syndrome

The disclosure relates to pharmacotherapy of a psychiatric disorder which is schizophrenia and/or anxiety, wherein schizophrenia includes schizophrenia related disorders such as brief psychotic disorders, delusional disorders, schizoaffective disorders, and schizophreniform disorders, and anxiety includes panic disorders, obsessive-compulsive disorders (OCD), post-traumatic stress disorders (PTSD), social phobia or social anxiety disorders, specific phobia, and generalized anxiety disorders (GAD). The compounds of the disclosure are useful for the treatment of the above psychiatric disorders alone or in combination with other therapeutical agents effective in the treatment of schizophrenia and/or anxiety disorders.

Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders

A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]propanamides and their salts with pharmaceutically acceptable acids with high purity degree, in particular, with a content of dibenzyl derivatives impurities lower than 0.03%, preferably lower than 0.01% by weight. The process is carried out by submitting the Schiff bases intermediates 2-[4-(3- and 2-fluorobenzyloxy)benzylideneamino]propanamides to catalytic hydrogenation in the presence of a heterogeneous catalyst in a protic organic solvent.

Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides

Methods of using certain &#x3b1;-aminoamide derivatives to treat lower urinary tract disorders. The therapeutic agents of the invention are able to reduce or even stop the lower urinary tract disorders substantially without side effects.

Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders

A monoclonal antibody is provided which is able to neutralize both human TNF .alpha. and TNF .beta., or a binding fragment thereof. A stable hybridoma cell line and progeny thereof are also provided which secrete such a monoclonal antibody. The monoclonal antibody or a fragment thereof may be used to detect the content of human TNF in a sample of body fluid.

Monoclonal antibodies against human Tumor Necrosis Factor .alpha.

Growing community of inventors

Cologno Monzese, Italy

Elena Barbanti